1. Home
  2. KBDC vs GHRS Comparison

KBDC vs GHRS Comparison

Compare KBDC & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KBDC
  • GHRS
  • Stock Information
  • Founded
  • KBDC 2021
  • GHRS 2018
  • Country
  • KBDC United States
  • GHRS Ireland
  • Employees
  • KBDC N/A
  • GHRS N/A
  • Industry
  • KBDC
  • GHRS Biotechnology: Pharmaceutical Preparations
  • Sector
  • KBDC
  • GHRS Health Care
  • Exchange
  • KBDC Nasdaq
  • GHRS Nasdaq
  • Market Cap
  • KBDC 1.1B
  • GHRS 925.2M
  • IPO Year
  • KBDC N/A
  • GHRS 2021
  • Fundamental
  • Price
  • KBDC $16.07
  • GHRS $15.58
  • Analyst Decision
  • KBDC Buy
  • GHRS Strong Buy
  • Analyst Count
  • KBDC 4
  • GHRS 8
  • Target Price
  • KBDC $16.38
  • GHRS $30.63
  • AVG Volume (30 Days)
  • KBDC 136.2K
  • GHRS 187.7K
  • Earning Date
  • KBDC 08-11-2025
  • GHRS 09-02-2025
  • Dividend Yield
  • KBDC 11.77%
  • GHRS N/A
  • EPS Growth
  • KBDC N/A
  • GHRS N/A
  • EPS
  • KBDC N/A
  • GHRS N/A
  • Revenue
  • KBDC N/A
  • GHRS N/A
  • Revenue This Year
  • KBDC $193.84
  • GHRS N/A
  • Revenue Next Year
  • KBDC $12.68
  • GHRS N/A
  • P/E Ratio
  • KBDC N/A
  • GHRS N/A
  • Revenue Growth
  • KBDC N/A
  • GHRS N/A
  • 52 Week Low
  • KBDC $13.93
  • GHRS $6.00
  • 52 Week High
  • KBDC $17.99
  • GHRS $20.50
  • Technical
  • Relative Strength Index (RSI)
  • KBDC N/A
  • GHRS 67.14
  • Support Level
  • KBDC N/A
  • GHRS $14.20
  • Resistance Level
  • KBDC N/A
  • GHRS $15.54
  • Average True Range (ATR)
  • KBDC 0.00
  • GHRS 1.07
  • MACD
  • KBDC 0.00
  • GHRS 0.29
  • Stochastic Oscillator
  • KBDC 0.00
  • GHRS 93.84

About KBDC Kayne Anderson BDC Inc. Common Stock

Kayne Anderson BDC Inc is an externally managed, closed-end, non-diversified management investment company that has elected to be regulated as a business development company that invests primarily in first-lien senior secured loans, with a secondary focus on unitranche and split-lien loans to middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation primarily through debt investments in middle-market companies.

About GHRS GH Research PLC

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.

Share on Social Networks: